Department of Medicine

Acute Hematologic Malignancies Symposium

Master
Heading

2021 Symposium Highlights

Content

The Third Annual Third Annual Hematologic Malignancy Symposium was held March 13, 2021. View the following for information on the past event:

Symposium Overview

During our third symposium, we brought together national and international acclaimed leukemia scientists to discuss recent advances in clonal hematopoiesis, low/high risk myelodysplastic syndrome, targeted AML therapy with emphasis in novel HMA plus BCL-2 inhibitor combination, advances in P53 myeloid malignancies therapies.

During our 2021 symposium, we incorporated state-of- the-art lectures on post induction HMA treatment, mechanisms of FLT3 inhibition
resistance and how to manage elderly AML patients. A highly interactive update on HMA plus BCL-2 inhibitor therapy was followed by a panel discussion on post induction AML maintenance.

Additionally, the symposium provided important novel development in MDS and AML pathogenesis leading to unique opportunity for clinical trial design ideas.